PRDX1 and plasma cell myeloma: PRDX1 was identified as a tumor-associated antigen in esophageal squamous cell carcinoma [33] and acted via mTOR/p70S6K pathway [34]; its overexpression was demonstrated in multiple myeloma [35], was associated with tumour angiogenesis and progression in human hepatocellular cancer [36], provided resistance to docetaxel treatment of lung cancer [37] and to alkylating agent bis-chloroethyl nitroso urea of oligodendroglial tumors [38].